Antibiotics effects in a rabbit model of Chlamydia pneumoniae - Induced atherosclerosis

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Fong, Ignatius W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; IMMUNOGLOBULIN G ANTIBODY; MOXIFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CONFERENCE PAPER; MYCOPLASMA PNEUMONIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; STROKE;

EID: 0034100076     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315607     Document Type: Conference Paper

References (28)

1. 1. Ross R. Atherosclerosis an Inflammatory disease. N Engl J Med 1999;340: 115-26.
2. 2. Fong IW. Emerging relationships of infectious diseases and coronary heart disease and atherosclerosis. Can Med Assoc J 2000 (in press).
3. 3. Danesh J, Collins R, Petro R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
4. 4. Grayston JT, Campbell LA. The role of Chlamydia pneumoniae in atherosclerosis. Clin Infect Dis 1999;28:993-4.
5. 5. Jackson AL, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-90.
6. 6. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in arteries: The facts, their interpretation, and future studies [review]. J Clin Pathol 1998;51: 793-7.
7. 7. Bell TA, Kuo CC, Wang SP, Grayston JT. Experimental infection of baboons (papio-cynocephalus arubis) with Chlamydia pneumoniae strain TWAR. J Infect 1989;19:47-9.
8. 8. Yang ZP, Kuo CC, Grayston JT. A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect Immun 1993;61:2037-40.
9. 9. Holland SM, Taylor HR, Gaydos CA. Kappas EW, Quinn TC. Experimental infection with Chlamydia pneumoniae in non-human primates. Infect Immun 1990;58:593-7.
10. 10. Moazed TC, Kuo CC, Patton DL. Grayston JT, Campbell LA. Experimental rabbit models of Chlamydia pneumoniae infection. Am J Pathol 1996; 148: 667-76.
11. 11. Yang Z, Kuo CC, Grayston JT. Systemic dissemination of Chlamydia pneumoniae following intranasal inoculation in mice. J Infect Dis 1995;171: 736-8.
12. 12. Finging G, Hanke H. Nikolai Nikolajewitsch Anitschkow (1885 1964) established the cholesterol fed rabbit as a model for atherosclerosis research. Atherosclerosis 1997;135:1-7.
13. 13. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT. Kuo CC. Chlamydia pnetimomae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999;180:238-41.
14. 14. Hu H. Pierce GN, Zhang G. Atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
15. 15. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175: 883-90.
16. 16. Fong IW, Chiu B, Viira E, Fong MW. Jang D. Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
17. 17. Fong IW, Chiu B, Viira E, Jang D, Mahony JD. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999;67:6048-55.
18. 18. Laitinan K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-5.
19. 19. Muhlstein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and the treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-6.
20. 20. Richardson M, De Reske M, Delaney K, Fletch A, Wilcox LH, Kinlough-Rathbone RL. Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-I. Am J Pathol 1997;151:1009-17.
21. 21. Hammerschalg MR. Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
22. 22. Rakita RM. Intracellular activity, potential clinical uses of antibiotics. ASM News 1998;64:570-5.
23. 23. Daley SJ, Klemp KF, Guyton JR. Rogers KA. Cholesterol-fed and caseinfed rabbit models of atherosclerosis. Part 2. Arterioscler Thromb 1994; 14:105-14.
24. 24. Stary HC. The histological classification of atherosclerotic lesions in human coronary arteries. In: Fuster V. Ross R. Topol EJ, eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven. 1996: 463-74.
25. 25. Fong IW, Chiu B, Viira E, Jang D, Fong MW, Mahony JB. Can antibiotic (macrolide) prevent Chlamydia pneumoniae induced atherosclerosis in a rabbit model? Clin Diag Lab Immun 1999;6:891-4.
26. 26. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. The value of clarithromycin in preventing early atherosclerotic lesions after Chlamydia pneumoniae infection [abstract]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
27. 27. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998;41(suppl B):47-50.
28. 28. Fong IW, Chiu B. Viira E, Jang D. Mahony JB. Prevention of atherosclerosis induced by Chlamydia pneumoniae by early treatment with moxifloxacin and doxycycline [abstract]. In: Program and abstracts of the 9th International Congress on Infectious Diseases, Buenos Aires. April 2000.